Nabi Biopharmaceuticals (NABI) Reports Q3 Loss of $0.12

Nabi Biopharmaceuticals (NASDAQ: NABI) reported Q3 EPS of ($0.12), versus ($0.07) reported last year. Revenue for the quarter came in at $632 thousand, versus $1.1 million reported last year.

For earnings history and earnings-related data on Nabi Biopharmaceuticals (NABI) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• Yatsen Holding (YSG) Reports Q2 Loss of $0.16
• Scotiabank Starts Block Inc. (XYZ) at Sector Perform